Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Jubilant Life has got USFDA approval for migraine treatment drug

On Tuesday, Jubilant Life Science said that it has received the US health regulator’s approval for its generic version of Merck’s acute migraine treatment medicine, Maxalt-MLT.

The company said in a BSE filing that it has got Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Rizatriptan Benzoate orally disintegrating tablets, 5 mg and 10 mg.

It further said that the medicine is the generic version of Maxalt-MLT orally-disintegrating, 5 mg and 10 mg tablets of Merck which is indicated for the acute treatment of migraine in adults and paediatric patients.

Read EquityPandit’s CNX Pharma Outlook for this week 

Get Daily Prediction & Stocks Tips On Your Mobile